《TRIPS协定》药品专利强制许可制度的国际实践及我国的改革之路  

The International Practice of the Compulsory License System for drug patents in TRIPS Agreement and the Way of Reform in China

作　　者：李昌凤[1] Li Changfeng(CPC Henan Provincial Party School,Zhengzhou Henan 451000)

机构地区：[1]中共河南省委党校,河南郑州451000

出　　处：《创新科技》2018年第10期76-79,共4页Innovation science and technology

摘　　要：为应对全球严峻的公共健康形势,《TRIPs协定》构建了药品专利强制许可制度。在国际上发展中国家和发达国家立足本国需要在药品专利强制许可制度上均有所实践。为切实提高我国药品可及性,保障公共健康,我国应坚持"慎用而善用"的指导思想,实现药品专利强制许可法律规范体系化、科学化,扩大药品专利强制许可启动主体范围,完善药品专利强制许可事由,明确许可使用费标准。In response to the severe public health situation in the world,the TRIPS Agreement establishes a compulsory license system for drug patents.Both developing countries and developed countries in the world have to practice the compulsory license system of drug patents to stand on their own needs.In order to improve the availability of drugs and protect public health,China should adhere to the guiding ideology of"prudent use and good use",realize the systematic and scientific legal norms of compulsory license for drug patents,expand the scope of starting subject of compulsory license for drug patents,improve the cause of compulsory license for drug patents,and clarify the licensing fee standard.

关 键 词：《TRIPS协定》 药品专利 专利强制许可 公共健康 

分 类 号：D923.42[政治法律—民商法学]